All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
2 warning events since 2020; the latest 2025-01-27.
From the record
Universe Pharmaceuticals Inc.'s filings since 2020 show 2 warning events: a late-report notice (Form NT 10-K or NT 10-Q, 2 times, the latest 2025-01-27) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+185.1% a year over 7 filed years; profitable in 2 of 6.
From the record
Universe Pharmaceuticals Inc.'s 7 filed years say what it did: revenue went from $33 million in fiscal 2019 to $18 billion in fiscal 2025, up 185.1% a year; it rose in 2 of 6 years; the deepest fall was 45% from fiscal 2023 to fiscal 2025; net income was positive in 2 of 6 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 5.8/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Universe Pharmaceuticals Inc.'s shareholder treatment is put at 5.8 of 10 with a confidence of 20 of 100, because fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income, so the desk assumes the typical reading of its industry family, the median of 295 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -7%: lost 7¢ per shareholder dollar. Leverage 19%: owes 19¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-09-30, Universe Pharmaceuticals Inc. lost about 7 cents for every dollar of shareholders' money, and gross profitability: its products earned about 9 cents per dollar of everything the company owns. Leverage: it owed about 19 cents per dollar of assets (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 12% of 315 in its family; net margin -20.6%.
From the record
Universe Pharmaceuticals Inc.'s standing among 315 graded names in its industry family: revenue of $18 billion in fiscal 2025 ranks in the top 3% by size; a net margin of -20.6% ranks in the top 32%; revenue growth of 663% a year over the last 3 filed years ranks in the top 2% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
SI estimate 5.0/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Universe Pharmaceuticals Inc.'s leadership is put at 5.0 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 371 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
What are they set up to do next?
How much room does it have to grow?
bottom 38% of 273 in its family for room to expand.
From the record
Universe Pharmaceuticals Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $34 billion against no long-term debt tagged leaves 48.5% of its assets as net cash, top 33% of its family; cash from operations less capital spending is -29.8% of revenue (top 40%); a gross margin of 35.3% (bottom 20%); research spending of 3.8% of revenue (bottom 5%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 19% of 306 in its family for growth drivers.
From the record
Universe Pharmaceuticals Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 663% a year over the last three filed years against 185.1% over all 7, speeding up (top 1% of its family); the newest year grew -22.4% (bottom 26%); research spending grew 344.4% a year (top 1%); capital spending grew 1316.4% a year (top 1%) (its annual reports). Universe Pharmaceuticals Inc. reported 2 product lines in fiscal 2025: Revenue From Sales of Selfmanufactured TCMD Products at $13 billion (74%), Revenue From Sales of Thirdparty Products at $4.6 billion (26%); 0 of 2 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 35% of 233 in its family for expectations against reality.
From the record
Universe Pharmaceuticals Inc.'s newest year against its own record: revenue of $18 billion in fiscal 2025 came in 96.8% below the $550 billion its prior three years' pace pointed to (bottom 2% of its family); net income of $3.7 billion against a prior three-year average of $5.1 billion (top 43%); a net margin of -20.6% against -26% before (bottom 44%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made